key: cord-0694571-co6lyntf
authors: Capetti, Amedeo F; Stangalini, Carlo A; Borgonovo, Fabio; Mileto, Davide; Oreni, Letizia; Dedivitiis, Gianfranco; Lupo, Angelica; Cossu, Maria V; Bilardo, Lara; Giacomelli, Andrea; Galli, Massimo; Rizzardini, Giuliano
title: Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine
date: 2021-03-06
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab214
sha: c1805a6ce8981b43f656c82689ab898026ae3ad6
doc_id: 694571
cord_uid: co6lyntf

nan

M a n u s c r i p t 2 Dear Editor, We read with interest the manuscript by Paul Bieniasz [1] .

It is currently recommended that SARS-CoV-2 vaccines be administered regardless of exposure to SARS-CoV-2 infection [2] , though little is known about differences in response magnitude and durability in COVID-19-naïve and COVID-19-experienced subjects. Our pilot study was aimed to describe anti-spike production after the first dose of the BNT162b2 mRNA COVID-19 Vaccine in COVID-19-naïve and COVID-19-experienced subjects, using the DiaSorin"s LIAISON-CLIA-S1/S2® IgG solution, which has a 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT) [3] .

After signing written informed consent subjects were enrolled in the AntiCROWN longitudinal study of anti-S1/S2 response, approved by the "Comitato Etico Interaziendale Area 1", n. 2020/ST/158.

The pre-vaccine anti-S1/S2 levels for nursing home residents and staff (Elderly Nursing Home "San Giuseppe Moscati") were ascertained in June 2020 and subsequent SARS-CoV-2 exposure was monitored through nasopharyngeal swabs. Healthcare workers from the Luigi Sacco Hospital had anti-S1/S2 levels tested within 45 days before vaccination. Previous SARS-CoV-2 exposure was documented by a positive molecular swab or antigenic or serologic test. Participants were required to have a CLIA anti-S1/S2 test before and after the first vaccination.

Descriptive analyses of the variables were expressed as median (interquartile range IQR), or number (%). Continuous variables were compared using the nonparametric Mann-Whitney test. For the categorical variables the χ2 test was used, or Fisher"s exact test when needed. The antibody levels before and after vaccination were compared between groups with Mann-Whitney test or Kruskal-Wallis with Dunn"s test for pairwise multiple comparisons where appropriate.

A c c e p t e d M a n u s c r i p t 3 We enrolled 52 COVID-19-naïve and 69 COVID-19-experienced subjects. Sixty-one were healthcare workers, 10 from the Luigi Sacco Hospital, and 51 from the nursing home (22 COVID-19-naïve) and 60 hosts (30 COVID-19-naïve). Populations were homogeneous by age and gender. Serology was assessed after a median of 9 days [IQR 7-11] after vaccination.

We didn"t find significant differences in antibody responses by COVID-19 severity, as shown in [5] in 41 SARS-CoV-2-exposed and 68 unexposed subjects and both concluded that in COVID-19-experienced subjects a second shot is probably not useful. Our cohort adds data on the comparable antibody production by elderly subjects.

Given such evidence it is reasonable to reorganize the vaccination campaign, assessing baseline immunity to SARS-CoV-2 through anti-S antibodies. At a time when vaccine demand outstrips supply, adopting this health strategy would help populations achieve herd immunity faster using fewer vaccine doses.

Potential conflicts of interest. None of the authors has potential conflicts of interest to disclose. M a n u s c r i p t 

The case against delaying SARS-CoV-2 mRNA vaccine boosting doses

Updated Interim Recommendation for Allocation of COVID-19 Vaccine

A quantitative assay with correlation to neutralizing antibodies

A cautionary note on recall vaccination in ex-COVID-19 subjects

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-mRNA Vaccine

Mrs Laura Spizzico, Head Nurse of the "San Giuseppe Moscati" Elderly Nursing Home.

A c c e p t e d M a n u s c r i p t 4